Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00

Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD)

Story continues below

Today, Audentes Therapeutics Inc (NASDAQ:BOLD) stock received an upgrade by Chardan Capital from Neutral to Buy with a price target of $40.00.

There are 7 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Audentes Therapeutics Inc (NASDAQ:BOLD) is Buy with a consensus target price of $32.7678 per share, a potential 24.73% upside.

Some recent analyst ratings include

  • 2/25/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00
  • 2/1/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by Mizuho with a $45.00 price target
  • 1/31/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by Cowen
  • 1/31/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Hold rating reiterated by William Blair
  • 1/11/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) had its Buy rating reiterated by HC Wainwright with a $33.00 price target
  • 1/11/2019-Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Guggenheim with a price target of $35.00
  • On 12/24/2018 Louis G Lange, Director, sold 32,000 with an average share price of $18.62 per share and the total transaction amounting to $595,840.00.
  • On 11/15/2018 Louis G Lange, Director, sold 24,000 with an average share price of $22.49 per share and the total transaction amounting to $539,760.00.
  • On 10/1/2018 Matthew R Patterson, CEO, sold 21,000 with an average share price of $38.16 per share and the total transaction amounting to $801,360.00.
  • On 10/1/2018 Suyash Prasad, VP, sold 10,000 with an average share price of $36.88 per share and the total transaction amounting to $368,800.00.
  • On 9/28/2018 John T Gray, SVP, sold 87 with an average share price of $40.00 per share and the total transaction amounting to $3,480.00.
  • On 9/24/2018 Louis G Lange, Director, sold 33,000 with an average share price of $37.38 per share and the total transaction amounting to $1,233,540.00.
  • On 9/18/2018 Matthew R Patterson, CEO, sold 12,952 with an average share price of $40.00 per share and the total transaction amounting to $518,080.00.

About Audentes Therapeutics Inc (NASDAQ:BOLD)
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Recent Trading Activity for Audentes Therapeutics Inc (NASDAQ:BOLD)
Shares of Audentes Therapeutics Inc closed the previous trading session at 26,27 +0,53 2,06 % with 25.04 shares trading hands.

An ad to help with our costs